NLS Pharmaceutics Announces Publication of New Patent Application for Next-Gen Dual Non-Sulfonamide Orexin Receptor Agonists (DOXA) [Yahoo! Finance]
NLS Pharmaceutics Ltd. - Common Shares (NLSP)
Company Research
Source: Yahoo! Finance
biopharmaceutical company dedicated to pioneering therapies for rare and complex central nervous system disorders, today announced the publication of the latest patent application (PCT/WO2024115797) by Aexon Labs with the World Intellectual Property Organization (WIPO). The patent will be used by NLS pursuant to its existing and previously announced license agreement with Aexon Labs. "This new patent application covers groundbreaking advancements in a novel series of dual orexin receptor agonists targeting narcolepsy as the primary indication and neurodegenerative conditions such as Parkinson's disease as secondary indications," said Eric Konofal, MD, PhD, Chief Scientific Officer of NLS Pharmaceutics, President of Aexon Labs, and inventor of the Dual Orexin Receptor Agonist platform (DOXA). "This application highlights the continued commitment from NLS to pioneer therapeutic approaches to address significant unmet medical needs." Key Highlights : Innovative Dual Orexin Receptor
Show less
Read more
Impact Snapshot
Event Time:
NLSP
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NLSP alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NLSP alerts
High impacting NLS Pharmaceutics Ltd. - Common Shares news events
Weekly update
A roundup of the hottest topics
NLSP
News
- NLS Pharmaceutics Announces Publication of New Patent Application for Next-Gen Dual Non-Sulfonamide Orexin Receptor Agonists (DOXA)Accesswire
- NLS Pharmaceutics Reports Positive Results from Study KO-874 on Mazindol's Neuroprotective Effects in Narcoleptic-like Rat Model [Yahoo! Finance]Yahoo! Finance
- NLS Pharmaceutics Reports Positive Results from Study KO-874 on Mazindol’s Neuroprotective Effects in Narcoleptic-like Rat ModelAccesswire
- NLS Pharmaceutics Announces Receipt of Additional Staff Delisting Determination from NasdaqAccesswire
- NLS Pharmaceutics Announces Receipt of Staff Delisting Determination from Nasdaq; Intends to Request Hearing [Yahoo! Finance]Yahoo! Finance
NLSP
Sec Filings
- 6/11/24 - Form 6-K
- 6/6/24 - Form 6-K
- 5/31/24 - Form 6-K
- NLSP's page on the SEC website